BIVI

BioVie Inc. Class A · NASDAQ

Sector Health Technology
Industry Biotechnology
Website bioviepharma.com
Employees(FY) 18
ISIN US09074F4054

Performance

-26.64%

-45.87%

-32.86%

-57.66%

-84.92%

YTD

-85.27%

Profile

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Advanced Technical Analysis

Technical Analysis of BIVI 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 3 and the Technical Score at 21, both indicating weak performance. The Oscillators Score of 40 suggests a neutral stance, but overall, the combined scores point to a lack of bullish momentum in the market.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of BIVI

Stock Rank

Recent News & Updates

2024-11-19 19:00
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference(Globenewswire)
2024-11-03 19:00
BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded(Globenewswire)
2024-10-29 04:05
BioVie Inc. Announces Closing of Registered Direct Offering(Globenewswire)
2024-10-28 04:10
UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules(Globenewswire)
2024-10-28 03:13
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules(Globenewswire)
2024-10-24 04:10
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement(Globenewswire)
2024-10-23 03:24
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules(Globenewswire)
2024-10-22 21:19
BioVie Announces Stock Offering and Private Placement(Yahoo Finance)
2024-10-22 20:00
Join BioVie's Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024(Globenewswire)
2024-10-22 04:01
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement(Globenewswire)
2024-10-21 03:08
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules(Globenewswire)
2024-10-14 20:00
BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin(Globenewswire)
2024-10-10 21:00
BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV(Accesswire)
2024-09-30 20:00
BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin(Globenewswire)
2024-09-25 04:05
BioVie Inc. Announces Closing of Public Offering(Globenewswire)
2024-09-23 10:26
BioVie Inc. Announces Pricing of Public Offering(Globenewswire)
2024-09-23 04:05
BioVie Inc. Announces Proposed Public Offering(Globenewswire)
2024-09-15 20:00
BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID(Globenewswire)
2024-09-02 20:00
BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID(Yahoo Finance)
2024-08-26 20:45
BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting(Globenewswire)
2024-08-12 20:00
BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting(Globenewswire)
2024-08-11 19:30
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday(Investorplace)
2024-08-07 18:00
BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease(Globenewswire)
2024-08-06 04:40
BioVie Inc. Announces Reverse Stock Split(Globenewswire)
2024-07-04 21:00
BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV(Accesswire)
2024-06-24 20:00
BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at ATMRD 2024(Globenewswire)
2024-06-20 21:00
BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV(Accesswire)
2024-06-19 20:00
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress(Globenewswire)
2024-06-11 20:24
Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26(Globenewswire)
2024-06-03 20:00
BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID(Globenewswire)

Page 1 of 6

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.